With this approval in hand, the company is now accelerating and strengthening its sales and marketing activities to introduce its new therapeutic procedure into the major European markets, starting with Germany, as well as moving its business model into the next stage

This transaction increases the nominal capital of the company, until now EUR 3,773,198.00 divided into 3,773,198 shares at an imputed nominal value of EUR 1.00, by an amount of EUR 80,190.00, thus bringing its nominal capital to EUR 3,853,388.00

The new shares will be privately placed with German and international institutional investors

The commitment provides MagForce with flexible access to additional equity capital of up to EUR 20 million, thus ensuring that the company retains a sound basis of financial comfort as it enters the rapidly approaching commercialization phase and further expands its R&D pipeline.

Professor Heckl is considered one of the world’s leading experts in the field of nanotechnology. His commitment to ongoing research in nanotechnology from its very early stages and to building public awareness of this groundbreaking technology were recognized in 2004, when he received the European Union’s Descartes Prize for Science Communication

Dr. Peter Heinrich was co-founder of MediGene AG and served as its managing director and CEO from 1995 until the middle of 2009. MediGene is a biotechnology company listed on the Frankfurt Stock Exchange and included in the TecDax index which at that time was focused on the development of innovative pharmaceuticals in the fields of oncology/immunology and cardiology

Following successful completion of this conformity assessment procedure and EC type testing of the magnetic field applicator, MagForce will be able to apply the CE European conformity marking and to market its Nano-Cancer® therapy throughout the European Union

The primary study endpoint, which was to extend the median survival time following tumor recurrence by three months compared to a historical control group, was significantly exceeded in the actual results

MagForce Nanotechnologies AG has successfully completed patient recruitment for its study on recurrent glioblastoma, which is of critical importance for demonstrating the efficacy of its proprietary Nano-Cancer® therapy

Klaus Wowereit, who as Governing Mayor of Berlin serves as both mayor of the city and governor of the state, today visited MagForce Nanotechnologies AG along with representatives of the press corps